Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Fortress Biotech Inc

FBIO
Current price
1.65 USD -0.07 USD (-4.07%)
Last closed 1.7 USD
ISIN US34960Q1094
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 47 133 588 USD
Yield for 12 month +25.00 %
1Y
3Y
5Y
10Y
15Y
FBIO
21.11.2021 - 28.11.2021

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. Address: 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

14 USD

P/E ratio

Dividend Yield

Current Year

+84 513 000 USD

Last Year

+75 743 000 USD

Current Quarter

+14 855 000 USD

Last Quarter

+13 030 000 USD

Current Year

+55 623 000 USD

Last Year

+44 968 000 USD

Current Quarter

+8 314 000 USD

Last Quarter

+6 214 000 USD

Key Figures FBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -90 308 000 USD
Operating Margin TTM -168.76 %
PE Ratio
Return On Assets TTM -36.41 %
PEG Ratio -0.1
Return On Equity TTM -1739.64 %
Wall Street Target Price 14 USD
Revenue TTM 82 624 000 USD
Book Value 0.79 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -14.3 %
Dividend Yield
Gross Profit TTM -85 658 000 USD
Earnings per share -27.73 USD
Diluted Eps TTM -27.73 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -49.25 %

Dividend Analytics FBIO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History FBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:15
Payout Ratio
Last Split Date 10.10.2023
Dividend Date

Stock Valuation FBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.7184
Price Sales TTM 0.5705
Enterprise Value EBITDA -0.2934
Price Book MRQ 2.637

Financials FBIO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators FBIO

For 52 weeks

1.29 USD 4.43 USD
50 Day MA 1.73 USD
Shares Short Prior Month 2 350 733
200 Day MA 1.86 USD
Short Ratio 2.99
Shares Short 2 572 277
Short Percent 11.28 %